English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Zolpidem is a hypnotic drug from the imidazopyridine family that is chemically distinct from benzodiazepines (BDZ). Contrary to classic BDZ, zolpidem acts selectively on α 1 subunit-containing GABA-A benzodiazepine (BZ1) receptors. There are a considerable number of zolpidem dependence case reports in the recent literature. Regarding the similarities of zolpidem and BDZ in pharmacodynamic and addictive characteristics, it has been suggested that recommended detoxification protocols for short half-life BDZ may also be useful in high-dose zolpidem withdrawal management. Safety and effectiveness of phenobarbital for inpatient BDZ detoxification has been established and it may be useful for zolpidem detoxification, as shown in two case reports presented here.

Detoxification of high-dose zolpidem using phenobarbital and gabapentin: two case reports